BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND ETV1, DKFZp781L0674, 2115, ENSG00000006468, ER81, MGC120533, MGC104699, MGC120534
140 results:

  • 1. The Value of Combined Detection of Serum PSA, MALAT1 and TMPRSS2-etv1 in Evaluating the Progress and Prognosis of prostate cancer.
    Zhao G; Pan Z; Wang P
    Arch Esp Urol; 2023 Oct; 76(8):555-562. PubMed ID: 37960954
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. SET7/9-mediated methylation affects oncogenic functions of histone demethylase JMJD2A.
    Gu R; Kim TD; Song H; Sui Y; Shin S; Oh S; Janknecht R
    JCI Insight; 2023 Oct; 8(20):. PubMed ID: 37870957
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Cleavage and Polyadenylation-Specific Factor 4 (CPSF4) Expression Is Associated with Enhanced prostate cancer Cell Migration and Cell Cycle Dysregulation, In Vitro.
    Choudhry M; Gamallat Y; Ghosh S; Bismar TA
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629142
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Development and characterization of an etv1 rabbit monoclonal antibody for the immunohistochemical detection of etv1 expression in cancer tissue specimens.
    Schafer C; Young D; Singh H; Jayakrishnan R; Banerjee S; Song Y; Dobi A; Petrovics G; Srivastava S; Srivastava S; Sesterhenn IA; Chesnut GT; Tan SH
    J Immunol Methods; 2023 Jul; 518():113493. PubMed ID: 37196930
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Glycyl-tRNA Synthetase (GARS) Expression Is Associated with prostate cancer Progression and Its Inhibition Decreases Migration, and Invasion In Vitro.
    Khosh Kish E; Gamallat Y; Choudhry M; Ghosh S; Seyedi S; Bismar TA
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901698
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Conditional gene regulation models demonstrate a pro-proliferative role for growth hormone receptor in prostate cancer.
    Unterberger CJ; McIlwain SJ; Tsourkas PK; Maklakova VI; Prince JL; Onesti A; Hu R; Kopchick JJ; Swanson SM; Marker PC
    Prostate; 2023 Apr; 83(5):416-429. PubMed ID: 36562110
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A review on the role of PCGEM1 lncRNA in cancer.
    Ghafouri-Fard S; Khoshbakht T; Hussen BM; Baniahmad A; Taheri M; Mokhtari M
    Pathol Res Pract; 2022 Dec; 240():154223. PubMed ID: 36403313
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The
    Gupta N; Song H; Wu W; Ponce RK; Lin YK; Kim JW; Small EJ; Feng FY; Huang FW; Okimoto RA
    Elife; 2022 Nov; 11():. PubMed ID: 36383412
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Transcriptomes of prostate cancer with TMPRSS2:ERG and Other ETS Fusions.
    Stopsack KH; Su XA; Vaselkiv JB; Graff RE; Ebot EM; Pettersson A; Lis RT; Fiorentino M; Loda M; Penney KL; Lotan TL; Mucci LA
    Mol Cancer Res; 2023 Jan; 21(1):14-23. PubMed ID: 36125519
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Disparities in quality of life, social distress and employment outcomes in Australian cancer survivors.
    White VM; Lisy K; Ward A; Ristevski E; Clode M; Webber K; Emery J; Ijzerman MJ; Afshar N; Millar J; Gibbs P; Evans S; Jefford M
    Support Care Cancer; 2022 Jun; 30(6):5299-5309. PubMed ID: 35279769
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.
    Chi P; Qin LX; Nguyen B; Kelly CM; D'Angelo SP; Dickson MA; Gounder MM; Keohan ML; Movva S; Nacev BA; Rosenbaum E; Thornton KA; Crago AM; Yoon S; Ulaner G; Yeh R; Martindale M; Phelan HT; Biniakewitz MD; Warda S; Lee CJ; Berger MF; Schultz ND; Singer S; Hwang S; Chen Y; Antonescu CR; Tap WD
    J Clin Oncol; 2022 Mar; 40(9):997-1008. PubMed ID: 35041493
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. ETS factors in prostate cancer.
    Qian C; Li D; Chen Y
    Cancer Lett; 2022 Apr; 530():181-189. PubMed ID: 35033589
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Nerve spare robot assisted laparoscopic prostatectomy with amniotic membranes: medium term outcomes.
    Noël J; Mascarenhas A; Patel E; Reddy S; Sandri M; Bhat S; Moschovas M; Rogers T; Ahmed S; Stirt D; Patel V
    J Robot Surg; 2022 Oct; 16(5):1219-1224. PubMed ID: 35015249
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Analysis of a large prostate cancer family identifies novel and recurrent gene fusion events providing evidence for inherited predisposition.
    Raspin K; O'Malley DE; Marthick JR; Donovan S; Malley RC; Banks A; Redwig F; Skala M; Dickinson JL; FitzGerald LM
    Prostate; 2022 Apr; 82(5):540-550. PubMed ID: 34994974
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Percentage of Gleason pattern 4 and tumor volume predict adverse pathological stage and margin status at radical prostatectomy in grade Group 2 and grade Group 3 prostate cancers.
    Iakymenko OA; Lugo I; Briski LM; Nemov I; Punnen S; Kwon D; Pollack A; Stoyanova R; Parekh DJ; Jorda M; Gonzalgo ML; Kryvenko ON
    Prostate; 2021 Sep; 81(12):866-873. PubMed ID: 34184782
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Improving Global Surgical Oncology Benchmarks: Defining the Unmet Need for cancer Surgery in Ghana.
    Gaskill CE; Gyedu A; Stewart B; Quansah R; Donkor P; Mock C
    World J Surg; 2021 Sep; 45(9):2661-2669. PubMed ID: 34152449
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. NCOR1 may be a potential biomarker of a novel molecular subtype of prostate cancer.
    Tang L; Zhang L; Liu L; Dong L; Dong Y; Zhu W; Wang H
    FEBS Open Bio; 2020 Dec; 10(12):2678-2686. PubMed ID: 33058520
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with prostate cancer following Radical prostatectomy and Adjuvant Radiation Therapy.
    Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
    Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Dysregulation of cancer genes by recurrent intergenic fusions.
    Yun JW; Yang L; Park HY; Lee CW; Cha H; Shin HT; Noh KW; Choi YL; Park WY; Park PJ
    Genome Biol; 2020 Jul; 21(1):166. PubMed ID: 32631391
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy.
    Bicak M; Lückerath K; Kalidindi T; Phelps ME; Strand SE; Morris MJ; Radu CG; Damoiseaux R; Peltola MT; Peekhaus N; Ho A; Veach D; Malmborg Hager AC; Larson SM; Lilja H; McDevitt MR; Klein RJ; Ulmert D
    Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15172-15181. PubMed ID: 32532924
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 7.